Genetic and immunologic characteristics of colorectal cancer patients with KRAS mutations and predictive significance of tumor immune microenvironment in adjuvant chemotherapy  

作　　者：Zhengqi Wen Wenliang Li Chengmin Shi Junrui Ma Sihui Zhao Ruize Zhou Xihong Liu Rong Yang Zhiping Zhang Hushan Zhang Bo Li 

机构地区：[1]Department of Oncology,The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650032,China [2]The Third Affliated Hospital of Kunming Medical University(Yunnan Cancer Center),Kunming,Yunnan 650021,China [3]Gastrointestinal and Hernia Surgery,The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan 650032,China [4]School of Nursing,Yunnan University of Chinese Medicine,Kunming,Yunnan 650022,China [5]Department of General Surgery,The First People's Hospital of Yunnan Province,Kunming,Yunnan 650000,China [6]Department of General Surgery,The Affiliated Hospital of Yunnan University,Yunnan 650011,China [7]Medical Department,3D Medicines Inc.,Shanghai 201114,China [8]Zhaotong Health Vocational College,Zhaotong,Yunnan 657000,China

出　　处：《Genes & Diseases》2024年第3期43-46,共4页基因与疾病（英文）

基　　金：supported by the National Natural Science Foundation of China(No.81960100,81760511).

摘　　要：Colorectal cancer(CRC)is one of the most common cancers around the world,and it is one of the leading causes of cancer-related death.1 Although anti-EGFR therapy and immune checkpoint inhibitor(ICl)therapy are becoming more and more important for colorectal therapy,however,clinical outcomes of current treatments for metastatic CRC,especially with ICls,have been shown to be affected by the status of KRAS.Therefore,KRAS mutation status detection has become a very important diagnostic factor for managing metastatic CRC patients.

关 键 词：KRAS COLORECTAL patients 

分 类 号：R735.34[医药卫生—肿瘤]